Japan Antidepressants Market Insight
Published: 05 June 2026 | Report Format: Electronic (PDF)
The Japan antidepressants market is expected to grow at a CAGR of 4.62% driven by rising depression cases, an aging population, growing mental health awareness, increased adoption of novel therapies, and expanding psychiatric care infrastructure.
Japan Antidepressants Market Insights Forecasts to 2035
- The Japan Antidepressants Market Size Was Estimated USD 3.12 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 4.62% from 2025 to 2035
- The Japan Antidepressants Market Size is Expected to Rise Around USD 4.89 Billion by 2035
Notable Insights for the Japan Antidepressants Market
- Segmentation on the basis of Drug Class indicates that the Selective Serotonin Reuptake Inhibitors (SSRIs) & Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) segment holds the dominant position in the Japan Antidepressants Market in 2025 with a market share of nearly 55% due to their well-established safety profiles, broad prescriber familiarity, and extensive use across major depressive disorder and anxiety-related conditions in Japan's large outpatient psychiatric network.
- Segmentation on the basis of Application indicates that the Major Depressive Disorder (MDD) & Anxiety Disorders treatment segment holds the dominant position in the Japan Antidepressants Market in 2025 with a market share of around 61%, driven by Japan's estimated 5 million depression patients, rising elderly psychiatric case loads, and expanding national mental health screening programs across primary care facilities.
- Worldwide projected revenue of Otsuka Pharmaceutical Co., Ltd. in fiscal year 2025 is estimated at approximately USD 7.1 Billion, supported by growing demand for CNS therapies including antidepressant and antipsychotic medications across Japan and global markets.
- It is expected that growing investment in novel antidepressant mechanisms, rapid-onset therapies, and digital mental health integration will continue driving market expansion, where next-generation antidepressants such as neuroactive steroid-based treatments demonstrate symptom improvement up to 36% faster than conventional antidepressants, while reducing patient discontinuation rates by up to 29%.
Download the eBook (ToC)
Why Buy This Report
- Provides an in-depth analysis of the impact of evolving mental health awareness, aging demographic pressures, regulatory approvals of novel antidepressant therapies, and Japan’s national psychiatric care reform on the Japan Antidepressants Market growth trajectory.
- Delivers strategic insights covering drug class innovations such as neuroactive steroids, rapid-acting NMDA antagonists, multimodal antidepressants, precision psychiatry approaches, and AI-assisted treatment personalization platforms gaining traction across Japanese clinical settings.
- Helps stakeholders benchmark against competitors, assess investment potential in CNS drug development, evaluate generic erosion risks for established antidepressants, and identify expansion opportunities within Japan’s hospital, outpatient, and online pharmacy distribution channels.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations and companies involved within the Japan Antidepressants Market, along with a comparative evaluation primarily based on their product offerings, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Antidepressants Market
- Shionogi & Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Sumitomo Pharma Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Eisai Co., Ltd.
- Eli Lilly and Company
- Pfizer Inc.
- H. Lundbeck A/S
- Meiji Seika Pharma Co., Ltd.
- Mitsubishi Tanabe Pharma Corporation
Recent Developments:
- In December 2025, Shionogi & Co., Ltd. received approval for ZURZUVAE® 30 mg in Japan, introducing a novel fast-acting antidepressant for major depressive disorder supported by positive Phase 3 trial outcomes.
- In September 2024, Shionogi & Co., Ltd. submitted an NDA in Japan for zuranolone for major depressive disorder under its collaboration with Sage Therapeutics, Inc. holding regional commercialization rights.
Market Segmentation:
Japan Antidepressants Market, By Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Tricyclic Antidepressants (TCAs)
- Neuroactive Steroid & Novel Mechanism Antidepressants
- Monoamine Oxidase Inhibitors (MAOIs) & Others
Japan Antidepressants Market, By Therapeutic Application
- Major Depressive Disorder (MDD)
- Generalized Anxiety Disorder (GAD)
- Obsessive-Compulsive Disorder (OCD)
- Panic Disorder & Post-Traumatic Stress Disorder (PTSD)
- Bipolar Depression & Treatment-Resistant Depression
Japan Antidepressants Market, By Distribution Channel
- Hospital Pharmacies
- Retail & Community Pharmacies
- Online Pharmacies & Digital Health Platforms
- Psychiatric Outpatient Clinics
- Government & Public Health Institutions
Expert Views:
The Japan antidepressants market is set for meaningful and sustained growth over the coming decade, driven by the increasing social recognition of depression as a serious medical condition, a rapidly aging population with growing psychiatric care needs, and the arrival of novel drug classes that offer faster onset and improved tolerability compared to older treatments. The recent approval of rapid-acting neuroactive steroid antidepressants signals a significant shift in Japan’s treatment paradigm, while growing integration of digital mental health tools and telemedicine platforms is broadening access to psychiatric care beyond traditional hospital settings. Continued investment in precision psychiatry, innovative CNS drug pipelines by both domestic and international pharmaceutical companies, and policy-driven expansion of mental health screening programs will collectively sustain the upward market trajectory through 2035.
Author: Komal and Radhika By Spherical Insights and Consulting